[go: up one dir, main page]

WO2006005589A3 - Polypeptide species useful for the treatment of neurological disorders - Google Patents

Polypeptide species useful for the treatment of neurological disorders Download PDF

Info

Publication number
WO2006005589A3
WO2006005589A3 PCT/EP2005/007567 EP2005007567W WO2006005589A3 WO 2006005589 A3 WO2006005589 A3 WO 2006005589A3 EP 2005007567 W EP2005007567 W EP 2005007567W WO 2006005589 A3 WO2006005589 A3 WO 2006005589A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
neurological disorders
polypeptide species
species useful
polypeptide
Prior art date
Application number
PCT/EP2005/007567
Other languages
French (fr)
Other versions
WO2006005589A2 (en
Inventor
Lydie Bougueleret
Isabelle Cuisin
Eve Mahe
Anne Niknejad
Samia Reffas
Original Assignee
Geneprot Inc
Lydie Bougueleret
Isabelle Cuisin
Eve Mahe
Anne Niknejad
Samia Reffas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneprot Inc, Lydie Bougueleret, Isabelle Cuisin, Eve Mahe, Anne Niknejad, Samia Reffas filed Critical Geneprot Inc
Publication of WO2006005589A2 publication Critical patent/WO2006005589A2/en
Publication of WO2006005589A3 publication Critical patent/WO2006005589A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a new secreted polypeptide which was initially found downregulated in the bloodstream of Multiple Sclerosis patients and which has therapeutic applications for the treatment of neurological disorders. The invention also provides methods of using compositions including the polypeptides and polynucleotides encoding them for drug development.
PCT/EP2005/007567 2004-07-12 2005-07-12 Polypeptide species useful for the treatment of neurological disorders WO2006005589A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58724904P 2004-07-12 2004-07-12
US60/587,249 2004-07-12
US63924204P 2004-12-27 2004-12-27
US60/639,242 2004-12-27
US67726705P 2005-05-03 2005-05-03
US60/677,267 2005-05-03

Publications (2)

Publication Number Publication Date
WO2006005589A2 WO2006005589A2 (en) 2006-01-19
WO2006005589A3 true WO2006005589A3 (en) 2006-10-26

Family

ID=35784219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007567 WO2006005589A2 (en) 2004-07-12 2005-07-12 Polypeptide species useful for the treatment of neurological disorders

Country Status (1)

Country Link
WO (1) WO2006005589A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089934A2 (en) * 2002-04-19 2003-10-30 B.R.A.H.M.S Aktiengesellschaft Method for diagnosing inflammatory diseases and infections by the determination of lasp-1/lap-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089934A2 (en) * 2002-04-19 2003-10-30 B.R.A.H.M.S Aktiengesellschaft Method for diagnosing inflammatory diseases and infections by the determination of lasp-1/lap-1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PHILLIPS G. ET AL., J OF NEUROSCI. RES., vol. 78, 2004, pages 38 - 48, XP002390857 *
SCHREIBER V ET AL: "LASP-1, A NOVEL TYPE OF ACTIN-BINDING PROTEIN ACCUMULATING IN CELL MEMBRANE EXTENSIONS", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, vol. 4, no. 10, 1998, pages 675 - 687, XP008019832, ISSN: 1076-1551 *

Also Published As

Publication number Publication date
WO2006005589A2 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2004047755A3 (en) Fused bicyclic nitrogen-containing heterocycles
EP1578988A4 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2004022580A3 (en) Bh3 peptides and method of use thereof
AU2003239531A1 (en) Protein cages for the delivery of medical imaging and therapy
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
WO2007022239A3 (en) Pharmaceutical formulations for sustained drug delivery
IL182116A0 (en) Nanobodies tm against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neural diseases such as alzheimer's disease
SG149059A1 (en) Gastrointestinal proliferative factor and uses thereof
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
WO2002059143A3 (en) Therapeutic peptides for demyelinating conditions
ZA200702318B (en) Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease
WO2003039539A3 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
ZA200500882B (en) Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis of treatment or liver disorders and epithelial cancer
WO2006048450A3 (en) Peptides for use in the treating obesity
WO2006048452A3 (en) Peptides for use in treating of obesity
WO2005014635A3 (en) Secreted polypeptide species reduced in cardiovascular disorders
WO2005015206A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2006005589A3 (en) Polypeptide species useful for the treatment of neurological disorders
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2004106941A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2006069739A3 (en) Polypeptide species useful for the treatment of neurological disorders
WO2005123113A3 (en) Interferon compositions and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC, ( EPO FORM 1205A ) DATED 23.04.07.

122 Ep: pct application non-entry in european phase

Ref document number: 05763474

Country of ref document: EP

Kind code of ref document: A2